Top Stock Speculative: Aveo Oncology, +25% Today!
Aveo Oncology’s stock shows a massive buy signal after the company has announced that the final analysis of its phase 3 clinical trial with Tibsovo (Tivozanib) in patients with renal cell carcinoma will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2020 virtual meeting at the end of May. Tension is rising!
Since summer 2017, shares of Aveo came under massive sell pressure, after the company has received a recommendation by the FDA not to move forward with a filing for a marketing approval in the US for its lead drug candidate Tibsovo. The FDA’s concerns were mainly based on inclusive data on the overall survival of patients treated with Tibsovo. Aveo now plans to present the final analysis of these data at ASCO at the end of May.
If the data are conclusive and can fully address the FDA’s concerns, this stock is likelyto face a price explosion of several hundred percent in the next few months. Only for speculative buyers!
The full press release of Aveo Oncology can be accessed here.